Stock 6580 TAIRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TaiRx, Inc.

Equities

6580

TW0006580004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
37.6 TWD -2.97% Intraday chart for TaiRx, Inc. +1.08% +39.26%
04-11 TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,416 1,177 2,579 4,809 3,378 2,435
Enterprise Value (EV) 1 887.3 859.7 1,910 4,267 3,035 1,788
P/E ratio -6.76 x -5.25 x -12 x -38.2 x -15.8 x -11.7 x
Yield - - - - - -
Capitalization / Revenue 944 x 373 x 768 x 935 x 488 x 479 x
EV / Revenue 591 x 272 x 569 x 830 x 438 x 352 x
EV / EBITDA -4.15 x -5.3 x -11.8 x -33.1 x -14.3 x -8.33 x
EV / FCF -376 x -3.92 x -21.6 x -54.3 x -28.2 x -15.3 x
FCF Yield -0.27% -25.5% -4.63% -1.84% -3.55% -6.53%
Price to Book 2.4 x 2.61 x 3.27 x 7.2 x 7.07 x 3.86 x
Nbr of stocks (in thousands) 57,213 61,137 89,227 89,227 90,200 90,200
Reference price 2 24.75 19.25 28.90 53.90 37.45 27.00
Announcement Date 24/04/19 22/04/20 21/04/21 06/06/22 11/04/23 11/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.501 3.156 3.359 5.141 6.923 5.082
EBITDA 1 -214.1 -162.1 -161.8 -129 -212 -214.6
EBIT 1 -215.3 -163.2 -163 -130.2 -213.1 -214.7
Operating Margin -14,342.17% -5,172.56% -4,853.29% -2,532.23% -3,077.89% -4,224.62%
Earnings before Tax (EBT) 1 -210.6 -220.8 -162.3 -127.5 -211.6 -212.3
Net income 1 -209.5 -217.8 -159.4 -125.6 -211.6 -212.3
Net margin -13,960.63% -6,900.03% -4,745.04% -2,443.36% -3,056.15% -4,177.33%
EPS 2 -3.663 -3.664 -2.411 -1.410 -2.370 -2.311
Free Cash Flow 1 -2.358 -219.5 -88.51 -78.63 -107.8 -116.7
FCF margin -157.06% -6,953.54% -2,635.07% -1,529.53% -1,557.33% -2,296.69%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 24/04/19 22/04/20 21/04/21 06/06/22 11/04/23 11/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 529 317 669 542 343 648
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.36 -219 -88.5 -78.6 -108 -117
ROE (net income / shareholders' equity) -30.3% -42% -25.9% -17.3% -36.6% -33.9%
ROA (Net income/ Total Assets) -17.3% -16.6% -15.4% -10.5% -21.5% -19.6%
Assets 1 1,212 1,314 1,038 1,192 985.5 1,082
Book Value Per Share 2 10.30 7.380 8.840 7.490 5.300 7.000
Cash Flow per Share 2 2.680 0.8400 1.020 0.3800 0.3900 1.450
Capex 1 0.11 - 0.11 0.67 - -
Capex / Sales 7.33% - 3.22% 12.97% - -
Announcement Date 24/04/19 22/04/20 21/04/21 06/06/22 11/04/23 11/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TAIRX, INC. Stock TaiRx, Inc.
+39.26% 132M
MODERNA, INC. Stock Moderna, Inc.
+29.77% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.00% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.99% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.22% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.41% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.62% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6580 Stock
  4. Financials TaiRx, Inc.